While the EMA’s Committee for Medicinal products for Human Use (CHMP) recommended a spree of treatments over the past week, Santhera’s Raxone (idebenone) was left out, rejected by the advisory panel and given a negative opinion in the treatment of Duchenne muscular dystrophy (DMD).
Image caption:
Image Credit: Santhera
